Literature DB >> 23359158

Quantification of murine pancreatic tumors by high-resolution ultrasound.

Stephen A Sastra1, Kenneth P Olive.   

Abstract

Ultrasonography is a powerful imaging modality that enables noninvasive, real-time visualization of abdominal organs and tissues. This technology may be adapted for use in mice through the utilization of higher frequency transducers, allowing for extremely high-resolution imaging of the mouse pancreas. This technique is particularly well suited to pancreas imaging due to the ultrasonographic properties of the normal mouse pancreas, easily accessible imaging planes for the head and tail of the mouse pancreas, and the comparative difficulty in imaging the mouse pancreas with other technologies. A suite of measurement tools is available to characterize the normal and diseased states of tissues. Of particular utility for cancer applications is the ability to use tomography to construct a 3D tumor volume, enabling longitudinal imaging studies to track tumor development, or response to therapies. Here, we describe a detailed method for performing high-resolution ultrasound to detect and measure pancreatic lesions in a genetically engineered mouse model of pancreatic ductal using the VisualSonics Vevo2100 High Resolution Ultrasound System. The method includes preparation of the animal for imaging, 2D and 3D image acquisition, and post-acquisition analysis of tumor volumes. The combined procedure has been utilized extensively by our group and others for the preclinical evaluation of novel therapeutic agents in the treatment of pancreatic ductal adenocarcinoma (Olive et al., Science 324:1457-1461, 2009; Cook et al., Methods Enzymol 439:73-85, 2008; Singh et al., Nat Biotechnol 28:585-593, 2010; Beatty et al., Science 331:1612-1616, 2011).

Entities:  

Mesh:

Year:  2013        PMID: 23359158      PMCID: PMC3879959          DOI: 10.1007/978-1-62703-287-2_13

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  8 in total

1.  Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations.

Authors:  Ralph H Hruban; N Volkan Adsay; Jorge Albores-Saavedra; Miriam R Anver; Andrew V Biankin; Gregory P Boivin; Emma E Furth; Toru Furukawa; Alison Klein; David S Klimstra; Gunter Kloppel; Gregory Y Lauwers; Daniel S Longnecker; Jutta Luttges; Anirban Maitra; G Johan A Offerhaus; Lucía Pérez-Gallego; Mark Redston; David A Tuveson
Journal:  Cancer Res       Date:  2006-01-01       Impact factor: 12.701

Review 2.  Tumor-suppressor genes in pancreatic cancer.

Authors:  R H Hruban; G J Offerhaus; S E Kern; M Goggins; R E Wilentz; C J Yeo
Journal:  J Hepatobiliary Pancreat Surg       Date:  1998

3.  Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models.

Authors:  Mallika Singh; Anthony Lima; Rafael Molina; Patricia Hamilton; Anne C Clermont; Vidusha Devasthali; Jennifer D Thompson; Jason H Cheng; Hani Bou Reslan; Calvin C K Ho; Timothy C Cao; Chingwei V Lee; Michelle A Nannini; Germaine Fuh; Richard A D Carano; Hartmut Koeppen; Ron X Yu; William F Forrest; Gregory D Plowman; Leisa Johnson
Journal:  Nat Biotechnol       Date:  2010-05-23       Impact factor: 54.908

4.  Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice.

Authors:  Sunil R Hingorani; Lifu Wang; Asha S Multani; Chelsea Combs; Therese B Deramaudt; Ralph H Hruban; Anil K Rustgi; Sandy Chang; David A Tuveson
Journal:  Cancer Cell       Date:  2005-05       Impact factor: 31.743

5.  CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.

Authors:  Gregory L Beatty; Elena G Chiorean; Matthew P Fishman; Babak Saboury; Ursina R Teitelbaum; Weijing Sun; Richard D Huhn; Wenru Song; Dongguang Li; Leslie L Sharp; Drew A Torigian; Peter J O'Dwyer; Robert H Vonderheide
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

Review 6.  K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization.

Authors:  R H Hruban; A D van Mansfeld; G J Offerhaus; D H van Weering; D C Allison; S N Goodman; T W Kensler; K K Bose; J L Cameron; J L Bos
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

7.  K-Ras-driven pancreatic cancer mouse model for anticancer inhibitor analyses.

Authors:  Natalie Cook; Kenneth P Olive; Kristopher Frese; David A Tuveson
Journal:  Methods Enzymol       Date:  2008       Impact factor: 1.600

8.  Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.

Authors:  Kenneth P Olive; Michael A Jacobetz; Christian J Davidson; Aarthi Gopinathan; Dominick McIntyre; Davina Honess; Basetti Madhu; Mae A Goldgraben; Meredith E Caldwell; David Allard; Kristopher K Frese; Gina Denicola; Christine Feig; Chelsea Combs; Stephen P Winter; Heather Ireland-Zecchini; Stefanie Reichelt; William J Howat; Alex Chang; Mousumi Dhara; Lifu Wang; Felix Rückert; Robert Grützmann; Christian Pilarsky; Kamel Izeradjene; Sunil R Hingorani; Pearl Huang; Susan E Davies; William Plunkett; Merrill Egorin; Ralph H Hruban; Nigel Whitebread; Karen McGovern; Julian Adams; Christine Iacobuzio-Donahue; John Griffiths; David A Tuveson
Journal:  Science       Date:  2009-05-21       Impact factor: 47.728

  8 in total
  24 in total

1.  Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (LSL-Kras(G12D/+) ;LSL-Trp53(R172H/+) ;Pdx-1-Cre), Its Variants, and Their Application in Immuno-oncology Drug Discovery.

Authors:  Jae W Lee; Chad A Komar; Fee Bengsch; Kathleen Graham; Gregory L Beatty
Journal:  Curr Protoc Pharmacol       Date:  2016-06-01

2.  Elasticity mapping of murine abdominal organs in vivo using harmonic motion imaging (HMI).

Authors:  Thomas Payen; Carmine F Palermo; Stephen A Sastra; Hong Chen; Yang Han; Kenneth P Olive; Elisa E Konofagou
Journal:  Phys Med Biol       Date:  2016-07-12       Impact factor: 3.609

3.  Stromal response to Hedgehog signaling restrains pancreatic cancer progression.

Authors:  John J Lee; Rushika M Perera; Huaijun Wang; Dai-Chen Wu; X Shawn Liu; Shiwei Han; Julien Fitamant; Phillip D Jones; Krishna S Ghanta; Sally Kawano; Julia M Nagle; Vikram Deshpande; Yves Boucher; Tomoyo Kato; James K Chen; Jürgen K Willmann; Nabeel Bardeesy; Philip A Beachy
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-14       Impact factor: 11.205

4.  Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma.

Authors:  Andrew D Rhim; Paul E Oberstein; Dafydd H Thomas; Emily T Mirek; Carmine F Palermo; Stephen A Sastra; Erin N Dekleva; Tyler Saunders; Claudia P Becerra; Ian W Tattersall; C Benedikt Westphalen; Jan Kitajewski; Maite G Fernandez-Barrena; Martin E Fernandez-Zapico; Christine Iacobuzio-Donahue; Kenneth P Olive; Ben Z Stanger
Journal:  Cancer Cell       Date:  2014-05-22       Impact factor: 31.743

5.  Cancer stem cell marker phenotypes are reversible and functionally homogeneous in a preclinical model of pancreatic cancer.

Authors:  Joseph S Dosch; Elizabeth K Ziemke; Amrith Shettigar; Alnawaz Rehemtulla; Judith S Sebolt-Leopold
Journal:  Cancer Res       Date:  2015-09-10       Impact factor: 12.701

6.  Utilizing High Resolution Ultrasound to Monitor Tumor Onset and Growth in Genetically Engineered Pancreatic Cancer Models.

Authors:  Robert-Guenther Goetze; Soeren M Buchholz; Shilpa Patil; Golo Petzold; Volker Ellenrieder; Elisabeth Hessmann; Albrecht Neesse
Journal:  J Vis Exp       Date:  2018-04-07       Impact factor: 1.355

7.  Cysteine depletion induces pancreatic tumor ferroptosis in mice.

Authors:  Michael A Badgley; Daniel M Kremer; H Carlo Maurer; Kathleen E DelGiorno; Ho-Joon Lee; Vinee Purohit; Irina R Sagalovskiy; Alice Ma; Jonathan Kapilian; Christina E M Firl; Amanda R Decker; Steve A Sastra; Carmine F Palermo; Leonardo R Andrade; Peter Sajjakulnukit; Li Zhang; Zachary P Tolstyka; Tal Hirschhorn; Candice Lamb; Tong Liu; Wei Gu; E Scott Seeley; Everett Stone; George Georgiou; Uri Manor; Alina Iuga; Geoffrey M Wahl; Brent R Stockwell; Costas A Lyssiotis; Kenneth P Olive
Journal:  Science       Date:  2020-04-03       Impact factor: 47.728

8.  Pulsed High-Intensity Focused Ultrasound Enhances Delivery of Doxorubicin in a Preclinical Model of Pancreatic Cancer.

Authors:  Tong Li; Yak-Nam Wang; Tatiana D Khokhlova; Samantha D'Andrea; Frank Starr; Hong Chen; Jeannine S McCune; Linda J Risler; Afshin Mashadi-Hossein; Sunil R Hingorani; Amy Chang; Joo Ha Hwang
Journal:  Cancer Res       Date:  2015-07-27       Impact factor: 12.701

9.  Reverse-Contrast Imaging and Targeted Radiation Therapy of Advanced Pancreatic Cancer Models.

Authors:  Daniel L J Thorek; Robin M Kramer; Qing Chen; Jeho Jeong; Mihaela E Lupu; Alycia M Lee; Mary E Moynahan; Maeve Lowery; David Ulmert; Pat Zanzonico; Joseph O Deasy; John L Humm; James Russell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-06-09       Impact factor: 7.038

10.  Inactivation of the transcription factor GLI1 accelerates pancreatic cancer progression.

Authors:  Lisa D Mills; Lizhi Zhang; Ronald Marler; Phyllis Svingen; Maite G Fernandez-Barrena; Maneesh Dave; William Bamlet; Robert R McWilliams; Gloria M Petersen; William Faubion; Martin E Fernandez-Zapico
Journal:  J Biol Chem       Date:  2014-04-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.